Is general practitioner involvement in the initiation of opioids for chronic non-cancer pain associated with opioid dose and concurrent drug use?

Is the involvement of the regular general practitioner (GP) in the decision to initiate opioid treatment for chronic non-cancer pain (CNCP) associated with two main risk factors for serious adverse events: increased opioid dose and the concomitant use of prescribed benzodiazepines or benzodiazepine-related medications? An anonymous web-based survey was conducted in the county of Rogaland, Norway, during the spring of 2021. GPs who self-reported applying at least once for reimbursement of opioids prescribed to treat CNCP. They were asked to answer the survey based on the last patient for whom they recalled submitting a reimbursement application. 1) Total opioid dose in daily oral morphine equivalents (OMEQ). 2) Concurrent use of benzodiazepines and/or benzodiazepine-related drugs. The daily opioid dose was lower when the surveyed GPs initiated the opioid treatment (36 OMEQ, = 25), than when others had initiated the treatment (108 OMEQ, = 31, = 0.001). For concurrent use of benzodiazepine or benzodiazepine-related drugs, no significant difference was found (33%, = 9 with GP involvement . 47%, = 16, = 0.279 with no GP involvement). GP involvement in the initiation of opioid medication for CNCP was associated with a lower opioid dose being prescribed. GP involvement in the initiation of opioid prescriptions may facilitate safer prescribing.